Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interdisciplinary Communication | 1 | 2020 | 106 | 0.620 |
Why?
|
| Pemphigoid, Bullous | 1 | 2019 | 4 | 0.590 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 15 | 0.580 |
Why?
|
| Palliative Care | 1 | 2020 | 249 | 0.540 |
Why?
|
| Skin | 3 | 2016 | 422 | 0.520 |
Why?
|
| Critical Care | 1 | 2020 | 402 | 0.500 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2016 | 12 | 0.480 |
Why?
|
| Brachytherapy | 1 | 2016 | 40 | 0.480 |
Why?
|
| Complex Regional Pain Syndromes | 1 | 2015 | 2 | 0.470 |
Why?
|
| Paraplegia | 1 | 2015 | 8 | 0.460 |
Why?
|
| Epidural Abscess | 1 | 2015 | 9 | 0.460 |
Why?
|
| Leishmania mexicana | 1 | 2015 | 8 | 0.460 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2015 | 17 | 0.450 |
Why?
|
| Scleromyxedema | 1 | 2014 | 2 | 0.440 |
Why?
|
| Granuloma Annulare | 1 | 2014 | 4 | 0.440 |
Why?
|
| Exanthema | 2 | 2012 | 27 | 0.440 |
Why?
|
| Erythema | 2 | 2015 | 13 | 0.420 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2012 | 1 | 0.360 |
Why?
|
| beta-Lactamases | 3 | 2006 | 18 | 0.350 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 39 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 5 | 2016 | 801 | 0.330 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 166 | 0.320 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 4 | 0.310 |
Why?
|
| Paresthesia | 1 | 2009 | 7 | 0.310 |
Why?
|
| Benzenesulfonates | 1 | 2009 | 14 | 0.310 |
Why?
|
| Foot Dermatoses | 1 | 2009 | 6 | 0.310 |
Why?
|
| Drug Eruptions | 1 | 2009 | 17 | 0.310 |
Why?
|
| Klebsiella Infections | 3 | 2006 | 25 | 0.300 |
Why?
|
| Pyrroles | 1 | 2009 | 50 | 0.300 |
Why?
|
| Triage | 1 | 2011 | 135 | 0.300 |
Why?
|
| Indoles | 1 | 2009 | 112 | 0.300 |
Why?
|
| Escherichia coli Infections | 3 | 2006 | 90 | 0.290 |
Why?
|
| Pyridines | 1 | 2009 | 119 | 0.290 |
Why?
|
| Melanoma | 1 | 2011 | 333 | 0.260 |
Why?
|
| Ceftazidime | 1 | 2006 | 3 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 408 | 0.240 |
Why?
|
| Ceftriaxone | 1 | 2006 | 20 | 0.240 |
Why?
|
| Enterobacteriaceae | 1 | 2006 | 19 | 0.240 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 591 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 643 | 0.210 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1222 | 0.190 |
Why?
|
| Humans | 17 | 2023 | 65140 | 0.190 |
Why?
|
| Biopsy | 2 | 2016 | 456 | 0.190 |
Why?
|
| Middle Aged | 9 | 2016 | 18273 | 0.160 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2019 | 11 | 0.150 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 15 | 0.150 |
Why?
|
| Finland | 1 | 2019 | 20 | 0.150 |
Why?
|
| Physicians | 1 | 2023 | 474 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1141 | 0.130 |
Why?
|
| Cellulitis | 1 | 2016 | 16 | 0.120 |
Why?
|
| Amputation Stumps | 1 | 2015 | 1 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 15 | 0.120 |
Why?
|
| Thigh | 1 | 2015 | 28 | 0.120 |
Why?
|
| Blister | 1 | 2015 | 15 | 0.120 |
Why?
|
| Male | 8 | 2016 | 31047 | 0.110 |
Why?
|
| Mexico | 1 | 2015 | 39 | 0.110 |
Why?
|
| Travel | 1 | 2015 | 44 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 34 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 35 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2014 | 110 | 0.100 |
Why?
|
| Syndrome | 2 | 2011 | 180 | 0.100 |
Why?
|
| Pain | 1 | 2015 | 399 | 0.090 |
Why?
|
| PAX8 Transcription Factor | 1 | 2012 | 2 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 17 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2012 | 48 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 991 | 0.090 |
Why?
|
| Lasers, Dye | 1 | 2011 | 6 | 0.090 |
Why?
|
| Skin Diseases, Vascular | 1 | 2011 | 6 | 0.090 |
Why?
|
| Hospitals, General | 1 | 2011 | 18 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1559 | 0.080 |
Why?
|
| Microscopy | 1 | 2012 | 99 | 0.080 |
Why?
|
| Cutis Laxa | 1 | 2011 | 8 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 44 | 0.080 |
Why?
|
| Fever | 1 | 2011 | 65 | 0.080 |
Why?
|
| Citalopram | 1 | 2011 | 22 | 0.080 |
Why?
|
| Eosinophilia | 1 | 2011 | 37 | 0.080 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 29 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 5614 | 0.080 |
Why?
|
| Boston | 1 | 2011 | 258 | 0.080 |
Why?
|
| Niacinamide | 1 | 2009 | 33 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 896 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 32 | 0.080 |
Why?
|
| Female | 6 | 2015 | 34018 | 0.070 |
Why?
|
| Adult | 5 | 2015 | 17358 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5792 | 0.070 |
Why?
|
| Population Groups | 1 | 2006 | 14 | 0.060 |
Why?
|
| Klebsiella oxytoca | 1 | 2005 | 3 | 0.060 |
Why?
|
| Klebsiella | 1 | 2005 | 11 | 0.060 |
Why?
|
| Klebsiella pneumoniae | 1 | 2005 | 29 | 0.060 |
Why?
|
| Prognosis | 1 | 2009 | 1784 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2005 | 60 | 0.050 |
Why?
|
| Risk Factors | 2 | 2009 | 5429 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2016 | 208 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2011 | 6872 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2005 | 714 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 464 | 0.030 |
Why?
|
| Adolescent | 2 | 2006 | 6297 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 674 | 0.030 |
Why?
|
| Communication | 1 | 2023 | 596 | 0.030 |
Why?
|
| Aged | 3 | 2006 | 14965 | 0.030 |
Why?
|
| Prednisolone | 1 | 2011 | 11 | 0.020 |
Why?
|
| Linezolid | 1 | 2011 | 7 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2011 | 8 | 0.020 |
Why?
|
| Oxazolidinones | 1 | 2011 | 16 | 0.020 |
Why?
|
| Acetamides | 1 | 2011 | 17 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 28 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 463 | 0.020 |
Why?
|
| United States | 1 | 2023 | 8093 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 152 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 296 | 0.010 |
Why?
|
| Phylogeny | 1 | 2005 | 388 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 2620 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 3762 | 0.010 |
Why?
|